Skip to the main content

Acta Pharmaceutica, Vol. 69 No. 1, 2019.

Short communication, Note

https://doi.org/10.2478/acph-2019-0004

The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ

XUE WANG ; Department of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo 315000, China; Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo 315000, China
SHUAISHUAI HUANG ; Department of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo 315000, China
XIA XIN ; Department of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo 315000, China; Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo 315000, China
YU REN ; Department of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo 315000, China; Laboratory of Kidney Carcinoma, Urology and Nephrology Institute of Ningbo University, Ningbo 315000, China
GOUBIN WENG ; Ningbo University, School of Medicine, Ningbo 315211, China
PING WANG

Full text: english pdf 1.475 Kb

page 111-119

downloads: 631

cite

Abstract

Umbelliferone exhibits extensive pharmacological activity, including anti-immunomodulatory, anti-inflammatory and antigenotoxicity activities. However, its antitumor properties still remain unclear in human renal cell carcinoma (RCC) cells. Our results have revealed that treatment of human RCC cells (786-O, OS-RC-2, and ACHN) with umbelliferone reduced cell proliferation in a concentration-dependent manner and induced dose-dependent apoptotic events. In addition, cell cycle analysis determined that umbelliferone treatment induced cell cycle arrest in the G1 phase in a dose-dependent manner. Furthermore, western blotting analysis showed a dose-dependent decrease in Ki67, MCM2, Bcl-2, CDK2, CyclinE1, CDK4, and CyclinD1 and a dose-dependent increase in Bax in RCC cells cultured with umbelliferone. Similarly, umbelliferone exhibited a dose-dependent reduction of p110γ when using western blotting analyses. Taken together, these results provide an insight into the pharmacology regarding the potential application of umbelliferone, which contributes to cell death by decreasing p110γ protein expression.

Keywords

umbelliferone; renal cell carcinoma; p110γ; anticancer activity

Hrčak ID:

206649

URI

https://hrcak.srce.hr/206649

Publication date:

31.3.2019.

Visits: 1.282 *